Table 1.
Characteristics of the study population
| Characteristics | No infection (n = 2,466) % |
Infection (n = 210) % |
p-value |
|---|---|---|---|
| Age (in years) | 40.5 (17.3) | 45.8 (18.9) | < 0.001 |
| Age at first IBD ICD9 code (in years) | 34.0 (16.6) | 39.7 (19.6) | < 0.001 |
| Sex | 0.086 | ||
| Female | 52 | 58 | |
| Male | 48 | 42 | |
| Race | 0.18 | ||
| White | 89 | 87 | |
| Black | 7 | 10 | |
| Other | 4 | 3 | |
| Charlson comorbidity† | < 0.001 | ||
| 0 | 30 | 5 | |
| 1 or more | 70 | 95 | |
| Type of IBD | 0.30 | ||
| Crohn’s disease | 63 | 59 | |
| Ulcerative colitis | 37 | 41 | |
| Diabetes | < 0.001 | ||
| No | 92 | 81 | |
| Yes | 8 | 19 | |
| Medication use | |||
| Anti-TNF | 19 | 22 | 0.23 |
| Steroid | 31 | 62 | < 0.001 |
IBD – inflammatory bowel disease; Anti-TNF – monoclonal antibodies to tumor necrosis factor α (infliximab, adalimumab, certolizumab pegol)
†
Charlson index was modified to exclude diabetes and related complications